Clinical Scorecard: Exploring Quality of Life Challenges and Unaddressed Needs in Chronic Myeloid Leukemia: Findings from a Comprehensive Italian Nationwide Survey
At a Glance
Category
Detail
Condition
Chronic Myeloid Leukemia (CML)
Key Mechanisms
Tyrosine kinase inhibitors (TKIs) are central to treatment, with a focus on achieving Major Molecular Response (MMR) and Deep Molecular Response (DMR).
Target Population
Adult patients with Chronic Myeloid Leukemia (CML).
Care Setting
Oncology and hematology outpatient settings.
Key Highlights
26% of patients reported low or very low quality of life (QoL).
Fatigue, weakness, and muscle pain were the most common symptoms reported.
Female patients experienced a higher symptom burden and greater psychological distress.
Common treatment-related adverse events were frequently chronic.
Unmet needs included information on supportive services and long-term disease management.
Guideline-Based Recommendations
Diagnosis
Diagnosis of CML should be confirmed through cytogenetic and molecular testing.
Management
First- and second-generation TKIs should be used as first-line therapy, with consideration for newer agents in cases of resistance or intolerance.
Monitoring & Follow-up
Regular monitoring for treatment adherence and response is essential to achieve MMR and DMR.
Risks
Patients may develop resistance or intolerance to TKIs, impacting adherence and outcomes.
Patient & Prescribing Data
Adult patients with Chronic Myeloid Leukemia (CML) in Italy.
Adherence to prescribed treatment is crucial for achieving desired clinical outcomes, including DMR.
Clinical Best Practices
Engage patients in shared decision-making regarding their treatment options.
Provide clear information about disease management and treatment implications.
Monitor and address treatment-related symptoms to improve QoL.
by Elisabetta Abruzzese, Mario Annunziata, Felice Bombaci, Antonella Russo Rossi, Anna Galante, Alessandra Misto, Diletta Valsecchi, Evgeniia Gushchina, Carmen Fava
